Skip to main content
Appili Therapeutics Inc. logo

Appili Therapeutics Inc. — Investor Relations & Filings

Ticker · APLI TSX Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2026-03-30 Regulatory Filings
Country CA Canada
Listing TSX APLI

About Appili Therapeutics Inc.

https://appilitherapeutics.com/

Appili Therapeutics Inc. is a biopharmaceutical company focused on the acquisition and development of novel medicines targeting unmet needs across a broad spectrum of infectious diseases and biodefense. The company advances anti-infective therapies to provide solutions for patients and healthcare providers. Its pipeline includes LIKMEZ™ (ATI-1501), a novel oral taste-masked suspension of metronidazole for serious anaerobic and protozoal infections; ATI-1701, a potential first-in-class live-attenuated vaccine for tularemia (a serious biothreat); and ATI-1801, a novel topical antiparasitic product designed to treat disfiguring skin infections.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing Appili Therapeutics’ participation at the World Vaccine Congress Washington, highlighting collaborations, funding milestones, and exhibit details. It does not contain financial results, management changes, governance details, or a formal investor slide deck. Therefore it does not match specialized categories like Earnings Release, Annual Report, Investor Presentation, or Management Discussion. As a general corporate announcement not fitting any specific filing type, it falls into the fallback category “Regulatory Filings” (RNS).
2026-03-30 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 45-106F1 Report of Exempt Distribution', which is a standard regulatory filing in Canada used to report the distribution of securities under prospectus exemptions. This document details the issuer (Appili Therapeutics Inc.), the distribution dates, the types of securities issued (units and warrants), and the jurisdictions of the purchasers. It is a formal regulatory disclosure required by securities commissions and does not fit into categories like annual reports, earnings releases, or investor presentations. Therefore, it is classified as a Regulatory Filing.
2025-12-29 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Material Change Report' filed under National Instrument 51-102, which is a standard Canadian regulatory requirement for disclosing significant corporate events. The content details a private placement financing (issuance of units, warrants, and broker warrants). While it contains a news release as an attachment, the document itself is a formal regulatory filing detailing the capital structure change. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate description for a document reporting on a private placement and capital raise.
2025-12-29 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a private placement (a capital raising activity). It details the issuance of units, common shares, and warrants, and specifies the use of proceeds. This falls directly under the definition of 'Capital/Financing Update' (CAP), as it describes a company's fundraising and financing activities.
2025-12-18 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a non-brokered private placement of up to 30,000,000 units (common shares plus warrants), detailing pricing, warrant terms, closing conditions, use of proceeds and hold periods. This is clearly a financing transaction involving new share issuance rather than an earnings report, AGM materials, or other category. It falls under the category of announcements regarding new share issues and changes to the capital structure. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-11-05 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a company press release announcing Appili Therapeutics will present at the NATO CBRN Conference. It does not contain financial results, governance changes, voting outcomes, regulatory form references, or details of a formal investor deck. It does not fit into any specific financial or regulatory filing category (e.g., 10-K, IR, ER, M&A, director dealings, dividend notices). Therefore, it falls into the general Regulatory Filings fallback category (RNS).
2025-09-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.